Human papillomavirus type 16 E7 oncoprotein-derived peptide epitopes (HPV16 E7 peptide epitopes) (HPV16 E7 peptide epitopes)

Human papillomavirus type 16 (HPV16) E7 oncoprotein-derived peptide epitopes are short amino acid sequences derived from the E7 early protein, a primary driver of HPV-mediated oncogenesis [UniProt P03129, NCI Drug Dictionary]. The full-length E7 protein promotes malignant transformation by binding to and inducing the degradation of the retinoblastoma (Rb) tumor suppressor protein, which disrupts cell cycle control [UniProt P03129, PubMed 1.1.1]. Because E7 is constitutively and specifically expressed in HPV-transformed cells, its derived peptides serve as ideal tumor-associated antigens for immunotherapy [PubMed 1.1.2, NCI Drug Dictionary]. Therapeutic vaccines, including synthetic long peptides (SLPs) like ISA101 and multi-epitope formulations like PDS0101, utilize these sequences to stimulate a robust T-cell-mediated immune response [Kenter et al., 2008; Melief et al., 2020; PubMed 1.2.5]. These treatments aim to prime CD8+ cytotoxic T cells to recognize and eliminate HPV16-positive cancer cells while sparing healthy tissue. Clinical development focuses on enhancing the immunogenicity of these epitopes through the use of novel adjuvants, delivery systems, and combination therapies with checkpoint inhibitors.

Other names

HPV16 E7 peptidesE7-derived epitopesHuman papillomavirus 16 E7 antigenHPV16 E7 synthetic long peptidesHPV16 E7 SLP

These peptide epitopes are presented by Major Histocompatibility Complex (MHC) class I and II molecules on the surface of antigen-presenting cells or tumor cells. Drugs targeting these epitopes, such as therapeutic vaccines, aim to activate and expand antigen-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T cells [Kenter et al., 2008; PubMed 1.2.3]. These activated T cells then recognize the E7-derived peptides displayed on HPV16-infected or transformed cells, leading to targeted cell lysis and tumor regression [Melief et al., 2020; PubMed 1.2.5].